Mirabegron sustained-release orally disintegrating microtablets and a preparation method thereof

By using an ion exchange resin composed of sodium polystyrene sulfonate and potassium polycrylene to form a complex with mirabezon, the problem of rapid disintegration and sustained release of mirabezon sustained-release formulations in small-sized micro-tablets is solved, improving drug stability and ease of administration, making it suitable for elderly and pediatric patients.

CN123101482APending Publication Date: 2026-11-17SHANDONG DYNE MARINE BIOTECHCAL PHARM HLDG CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611599406.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing mirabezon extended-release formulations struggle to balance rapid disintegration, stable sustained release, and stable shaping within small-sized microtablets, and also present issues such as difficulty in swallowing, inflexible dosage adjustment, and inconvenient storage.

Method used

Mirabelon sustained-release orally disintegrating microtablets were prepared by using an ion exchange resin composed of sodium polystyrene sulfonate and potassium polycrylene in a ratio of 1:1 to 5:1, which was then mixed with pharmaceutically acceptable excipients. The complementary exchange site density and exchange selectivity of the two resins were utilized to improve the drug-resin binding rate. With the appropriate excipient ratio, rapid disintegration and sustained release were achieved.

Benefits of technology

It achieves rapid disintegration and stable sustained release, improves drug stability and formability, is suitable for elderly and pediatric patients, simplifies the administration process, and reduces storage risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101482A_ABST
    Figure CN123101482A_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a mirabegron sustained-release orally disintegrating microtablet and a preparation method thereof. The microtablet comprises a mirabegron-ion exchange resin complex and pharmaceutically acceptable excipients, and the ion exchange resin is a 1:1-5:1 compounded poly(styrene sulfonic acid sodium) and poly(carbophil potassium). The compounded resin forms a complex with mirabegron, and is then mixed with a filler, a disintegrating agent, a glidant and a lubricant. The powder is directly tabletted to obtain the microtablet. The compounded resin improves the drug-resin binding rate to more than 98.5%, reduces free drugs, avoids burst release, sticking or delayed disintegration of a single resin, enables the microtablet to be rapidly disintegrated in the oral cavity within 10-35 seconds, and maintains stable and slow release. The microtablet does not need to be taken with water, and the dosage can be flexibly adjusted, is suitable for patients with difficulty in swallowing, has good accelerated 6-month stability, has a simple process, and is suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical formulation technology, and in particular to a miraberione sustained-release orally disintegrating microtablet and its preparation method. Background Technology

[0002] The information disclosed in the background section of this invention is intended only to enhance the understanding of the overall background of the invention and is not necessarily to be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art.

[0003] Mirabelon is a β3-adrenergic receptor agonist for the treatment of overactive bladder. The available dosage forms in China and abroad are extended-release tablets and extended-release dry suspensions. Extended-release tablets must be swallowed whole and cannot be broken, chewed, or crushed, making them inconvenient for elderly patients, children, and other patients with swallowing difficulties, and the dosage cannot be adjusted flexibly. Extended-release dry suspensions need to be reconstituted with water, and after reconstitution, they can only be stored for 28 days, making them inconvenient to carry and store. Furthermore, there are safety concerns regarding the antibacterial agents, antioxidants, and other excipients in the formulation.

[0004] To improve compliance, existing technologies propose combining mirabezon with ion exchange resins to form a complex, which is then mixed with fillers, disintegrants, and other excipients and compressed into tablets for sustained release via ion exchange. However, the resulting tablets are sustained-release tablets, still requiring chewing, breaking, crushing, or dispersing in water before administration. Orally disintegrating microtablets, weighing only a few milligrams and with a small diameter, require rapid disintegration without water upon ingestion, while maintaining sustained release after disintegration. Directly miniaturizing existing mirabezon-ion exchange resin complexes presents challenges due to the limited drug loading and high formulation ratio. The resin's hygroscopicity, flowability, and compressibility dominate microtablet formation: small dies can lead to poor powder flow, large variations in filler content, sticking, insufficient hardness, or brittleness. Increasing pressure or adding release-inhibiting materials to maintain sustained release prolongs the disintegration time, failing to meet orally disintegrating requirements. Furthermore, high humidity storage can cause moisture absorption and clumping, reducing dissolution. Therefore, achieving rapid disintegration, stable sustained release, and stable tablet formation in small-sized microtablets remains a challenging technical problem. Summary of the Invention

[0005] In view of this, the present invention provides a miraberione sustained-release orally disintegrating microtablet and a method for preparing the same.

[0006] In a first aspect, the present invention provides a mirabezone sustained-release orally disintegrating microtablet, the mirabezone sustained-release orally disintegrating microtablet comprising a mirabezone-ion exchange resin complex and pharmaceutically acceptable excipients; The ion exchange resin is sodium polystyrene sulfonate and potassium polycrylene, and the ratio of sodium polystyrene sulfonate to potassium polycrylene is 1:1 to 5:1.

[0007] Preferably, the content of mirabezoni in the mirabezoni sustained-release orally disintegrating microtablets is 2wt% to 10wt%, and more preferably 7.15wt%.

[0008] Preferably, the total content of the ion exchange resin is 100wt% to 300wt% of the Miraberon content, and more preferably 200wt%.

[0009] Preferably, the Miraberon-ion exchange resin complex further includes a pH adjuster; The pH adjuster is present in an amount of 0.5 wt% to 3.3 wt% of the mirabezon content. The pH adjuster is one or more of hydrochloric acid, citric acid, and phosphoric acid.

[0010] Preferably, the pharmaceutically acceptable excipients include fillers, disintegrants, glidants, and lubricants.

[0011] Preferably, the filler is one or more of mannitol, microcrystalline cellulose, sorbitol, and isomalt, with mannitol and microcrystalline cellulose being the most preferred.

[0012] Preferably, the disintegrant is one or more of crospovidone, crospovidone sodium carboxymethyl cellulose, and sodium carboxymethyl starch.

[0013] Preferably, the flow aid is one or more of silica, colloidal silica, and talc. The lubricant is one or more of sodium stearate fumarate, stearic acid, magnesium stearate, and glyceryl behenate.

[0014] Preferably, the pharmaceutically acceptable excipients also include compound excipients; The composite excipient is selected from one or more of the following: mannitol-microcrystalline cellulose-crosslinked povidone-colloidal silica composite and mannitol-crosslinked povidone-polyvinyl acetate-povidone composite.

[0015] Secondly, the present invention provides a method for preparing the above-mentioned mirabezon sustained-release orally disintegrating microtablets, comprising the following steps: Miraberon, ion exchange resin, and pH adjuster were placed in a solvent, heated and stirred, and dried to prepare Miraberon-ion exchange resin composite powder. Miraberon-ion exchange resin complex powder was mixed with pharmaceutically acceptable excipients to obtain a mixture, which was then compressed into microplates.

[0016] Compared with the prior art, the present invention has achieved the following beneficial effects: (1) This invention utilizes an ion exchange resin composed of sodium polystyrene sulfonate and potassium polycrylene in a ratio of 1:1 to 5:1 to form a complex with mirabeeron, and successfully prepares sustained-release orally disintegrating microtablets with pharmaceutically acceptable excipients. After the sodium polystyrene sulfonate and potassium polycrylene are combined in a ratio of 1:1 to 5:1, they bind with mirabeeron. The exchange site density and exchange selectivity of the two types of resins are complementary, resulting in a drug-resin binding rate of over 98.5%, significantly higher than the approximately 86.7% level when sodium polystyrene sulfonate is used alone. This significantly reduces the amount of free drug in the material, avoiding the burst release caused by the rapid release of free drug in small, heavy, and large-surface-area microtablets. Simultaneously, the reduction in free drug fundamentally reduces the growth of hydrolytic impurities during long-term storage, accelerating the process so that all impurities meet limits and dissolution rates show no significant change after 6 months, indicating good product stability.

[0017] (2) When polycrylene potassium is used alone, the compound has high viscosity, and tablets made by small die are prone to sticking and slow disintegration. When sodium polystyrene sulfonate is used alone, the binding rate is low, the product is highly hygroscopic, and the hardness is insufficient. When the compound is used in this invention, polycrylene potassium provides suitable compressibility and hardness, while sodium polystyrene sulfonate improves material flow and disintegration behavior. The two work synergistically to make the total mixed powder have good flowability and small difference in content. The micro-tablets are pressed smoothly without sticking, have suitable hardness, and disintegrate rapidly. At the same time, the release curve is stable, and the two mutually restrictive characteristics of slow release and oral disintegration are unified within the same micro-tablet system.

[0018] (3) The high binding rate reduces the proportion of the complex in the formulation, leaving sufficient space for the introduction of excipients such as fillers and disintegrants, making it possible to prepare microtablets by direct compression of powder. The resulting microtablets weigh only a few milligrams, with precise dosage, flexible dosing, and no need for water administration. They achieve rapid disintegration within 10-35 seconds without damaging the sustained-release matrix, and the tableting is smooth, without sticking, and with suitable hardness (5-10 N). This significantly improves medication compliance in elderly and children with dysphagia, and eliminates the need for complex processes such as coating, making the process simple and suitable for industrial scale-up. Attached Figure Description

[0019] The accompanying drawings, which form part of this specification, are used to provide a further understanding of the invention. The illustrative embodiments and descriptions of the invention are used to explain the invention and do not constitute an undue limitation thereof. Obviously, those skilled in the art can obtain other drawings based on these drawings without any inventive effort.

[0020] Figure 1 Dissolution curves of mirabezone sustained-release orally disintegrating microtablets prepared in various embodiments of the present invention. Detailed Implementation

[0021] It should be noted that the following detailed descriptions are exemplary and intended to provide further illustration of the invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0022] The present invention will be further described in detail below with reference to specific embodiments. It should be noted that the specific embodiments are for explanation and not limitation of the present invention. Unless otherwise specified, the experimental methods described in the following embodiments are conventional methods; unless otherwise specified, the reagents and materials are commercially available.

[0023] Examples 1-3 Miraberon-ion exchange resin composites were prepared, and their formulation composition and Miraberon-ion exchange resin binding rate are shown in Table 1.

[0024] Preparation process: Mirabelon, sodium polystyrene sulfonate, potassium polycrylene, dilute hydrochloric acid, and purified water were placed in a round-bottom flask and stirred for 3 hours in a water bath at 40-60℃. The reaction solution was then spray-dried to remove moisture, yielding a Mirabelon-sodium polystyrene sulfonate complex. The resulting complex was then reconstituted, and the drug concentration in the supernatant was measured, and the binding rate was calculated.

[0025] Binding rate determination method and principle: Since the solubility of mirabéron in water at 37℃ is 3mg / ml, and mirabéron-sodium polystyrene sulfonate will not dissociate in water in the absence of ion exchange, the complex is added to the dissolution vessel, and the unbound mirabéron will dissolve into the water. The binding rate of API to resin is calculated by measuring the drug concentration in the water.

[0026] Table 1. Prescription composition and evaluation of Examples 1-3

[0027] The results showed that the binding rate of Miraberon to the ion exchange resin in Examples 1-3 was above 98.5%, indicating good binding.

[0028] Examples 4-9 Sustained-release orally disintegrating microtablets were prepared using the Miraberon-ion exchange complexes prepared in Examples 1-3. The formulation composition and tableting conditions are shown in Table 2.

[0029] Preparation process: Raw material weighing and pretreatment: Weigh each raw material according to the prescription amount, then pass it through a 50-mesh sieve for later use; Mixing: Mix the sieved raw and auxiliary materials evenly to obtain the total powder mixture.

[0030] Tableting: The total powder mixture is compressed into tablets using a Φ2mm 10-pin circular shallow concave micro-die. Each tablet weighs approximately 6-8mg.

[0031] Hardness testing method: The hardness of the micro-tablets was measured using a Tianda Tianfa hardness tester. The micro-tablets were placed on the testing platform, and pressure was slowly applied radially until the tablets broke. The maximum pressure value (N) was recorded. Six tablets were randomly selected from each batch, and the hardness range of each sample was tested.

[0032] Table 2. Prescription composition and evaluation of Examples 4-9

[0033] Note: Examples 4-5 use the complex prepared in Example 1, Examples 6-7 use the complex prepared in Example 2, and Examples 8-9 use the complex prepared in Example 3.

[0034] Examples 4-9 show that using Mirabellon-sodium polystyrene sulfonate resin composites, with the addition of different proportions of composite excipients containing disintegrants, fillers, etc., can successfully prepare orally disintegrating microtablets, which can disintegrate rapidly and meet the characteristics of orally disintegrating tablets.

[0035] Examples 10-15 Sustained-release orally disintegrating microtablets were prepared using the Miraberon-ion exchange complexes prepared in Examples 1-3. The formulation composition and tableting conditions are shown in Table 3.

[0036] Preparation process: Raw material weighing and pretreatment: Weigh each raw material according to the prescription amount, then pass it through a 50-mesh sieve for later use; Mixing: Mix the sieved raw and auxiliary materials evenly to obtain the total powder mixture.

[0037] Tableting: The total powder mixture is compressed into tablets using a Φ2mm 10-pin circular shallow concave micro-die. Each tablet weighs approximately 6-8 mg.

[0038] Hardness testing method: The hardness of the micro-tablets was measured using a Tianda Tianfa hardness tester. The micro-tablets were placed on the testing platform, and pressure was slowly applied radially until the tablets broke. The maximum pressure value (N) was recorded. Six tablets were randomly selected from each batch, and the hardness range of each sample was tested.

[0039] Table 3. Formulation and Evaluation of Examples 10-15

[0040] Note: Examples 10-11 use the complex prepared in Example 1, Examples 12-13 use the complex prepared in Example 2, and Examples 14-15 use the complex prepared in Example 3.

[0041] Examples 10-15 show that orally disintegrating microtablets can be successfully prepared using Miraberon-Sodium Polystyrene Sulfonate resin composites, with isomalt or mannitol and microcrystalline cellulose as fillers, and cross-linked povidone as a disintegrant. These microtablets can disintegrate rapidly, which is consistent with the characteristics of orally disintegrating tablets.

[0042] Comparative Examples 1-2 Miraberon-ion exchange resin composites were prepared, and their formulation composition and Miraberon-ion exchange resin binding rate are shown in Table 4.

[0043] Table 4. Prescription composition and evaluation of Comparative Examples 1-2

[0044] Comparative Examples 3-4 Sustained-release orally disintegrating microtablets were prepared using Miraberon-ion exchange complexes prepared in Comparative Examples 1 and 2. The formulation composition and tableting conditions are shown in Table 5.

[0045] Table 5. Comparative Examples 3-4: Prescription Composition and Evaluation

[0046] Note: Comparative Example 3 uses the complex prepared in Comparative Example 1, and Comparative Example 4 uses the complex prepared in Comparative Example 2.

[0047] Preparation process and hardness testing method: same as in Examples 4-15.

[0048] Comparative Examples 5-6 Sustained-release orally disintegrating microtablets were prepared using Miraberon-ion exchange complexes prepared in Comparative Examples 1 and 2. The formulation composition and tableting conditions are shown in Table 6.

[0049] Table 6. Comparative Examples 5-6: Prescription Composition and Evaluation

[0050] Note: Comparative Example 5 uses the complex prepared in Comparative Example 1, and Comparative Example 6 uses the complex prepared in Comparative Example 2.

[0051] Preparation process and hardness testing method: same as in Examples 4-15.

[0052] Comparative Examples 4-6 show that when only sodium polystyrene sulfonate and Mirabella were used to prepare composites and pressed into micro-sheets, the pressed micro-sheets were pressed smoothly without sticking or punching, and the disintegration rate was relatively fast but the hardness was relatively low. When only potassium polycrylene and Mirabella were used to prepare composites and pressed into micro-sheets, the pressed micro-sheets had suitable hardness but there was a risk of sticking and punching during mass production, and the disintegration was relatively slow.

[0053] Experimental Example 1 Dissolution curve determination of Examples 4-15 and Comparative Examples 3-6 The method used was Method II (paddle method) of General Chapter 0931 in the 2025 edition of the Chinese Pharmacopoeia. The analytical method was HPLC, the dissolution medium was pH 6.8, the dissolution volume was 900 mL, the rotation speed was 50 rpm, and the temperature was 37 ± 0.5℃. The detection results are shown in Table 7 and... Figure 1 As shown.

[0054] Table 7. Determination of dissolution curves for Mirabelon sustained-release orally disintegrating microtablets

[0055] Table 7 (continued) Determination of dissolution profile of Mirabelon sustained-release orally disintegrating microtablets

[0056] Dissolution results in Examples 4-15 show that the mirabezon sustained-release orally disintegrating microtablets prepared according to this protocol can all be slowly released in vitro, which is consistent with the characteristics of a sustained-release formulation. The microtablets prepared in Example 2 have the best sustained-release effect, followed by the microtablets prepared in Example 1. Dissolution results in Comparative Examples 3-6 show that the microtablets prepared according to this protocol in Comparative Examples 4 and 6 can all be slowly released in vitro, which is consistent with the characteristics of a sustained-release formulation; however, according to the dissolution results in Comparative Examples 5 and 7, the microtablets exhibit obvious burst release, which does not meet the expected target.

[0057] Experimental Example 2 Taste evaluation of Examples 4-15 The palatability of the Miraberon sustained-release orally disintegrating microtablets from Examples 4-15 was evaluated using a direct taste assessment method. Examples 4-15 were used as samples 1-12, and palatability (taste) was used as the evaluation index. The samples were scored according to their taste.

[0058] Without disclosing the product information, 12 healthy subjects, aged 20-45 years (male-to-female ratio 1:1), participated in an oral taste test of mirabezone sustained-release orally disintegrating microtablets prepared in samples 1-7. Each subject was administered 10 tablets of the formulation. The procedure was as follows: 10 mirabezone sustained-release orally disintegrating microtablets were prepared. Before administration, volunteers rinsed their mouths three times with purified water, then held 10 mirabezone sustained-release orally disintegrating microtablets in their mouths (without swallowing), tasted the product, spat it out after 60 seconds, rinsed their mouths three times with purified water, and retested the next sample after a 10-minute interval. Palatability was assessed.

[0059] Taste evaluation criteria: Excellent (5 points): No bitterness, no unpleasant odor, no gritty feeling; Good (4 points): No bitterness, no unpleasant odor, slight gritty feel; General (3 points): Slightly bitter taste, no unpleasant odor, slight gritty feeling; Poor (2 points): Bitter taste, unpleasant odor, and gritty texture; Very poor (1 point): extremely bitter taste, with a distinct unpleasant odor and a noticeable gritty texture.

[0060] Table 7. Taste Evaluation of Mirabellon Sustained-Release Orally Disintegrating Microplates

[0061] Note: The palatability (taste) evaluation index is scored out of 5. It is evaluated from the perspective of whether the taste is good, and the average score is calculated.

[0062] The results showed that samples 1-12 were all rated as excellent or good, indicating that the sustained-release orally disintegrating microtablets of the present invention have a good taste.

[0063] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

[0064] Experimental Example 3 Stability studies were conducted on Examples 1-12 and Comparative Examples 3-6, following the guidelines of the 2025 edition of the Chinese Pharmacopoeia 9001 and ICH Q1. The samples were stored for 6 months at 40℃±2℃ and 75%±5% relative humidity, according to their commercially available packaging. Samples were taken once at the end of the 6th month to examine changes in sample mass. The results are shown in Table 8. Table 8 Summary of stability test results

[0065] Table 8 (continued) Summary of stability test results

[0066] Analysis of Table 8 shows that the levels of each impurity in the samples from Examples 1 to 15 at 0 days, 3 months, and 6 months are far below the limits for each impurity and the total impurities. In Comparative Examples 3 and 5, when placed under accelerated conditions for 3 months, impurity B exceeded the limit. This is likely because sodium polystyrene sulfonate is more likely to absorb moisture from the environment under accelerated conditions (typically 40°C / 75% RH) compared to potassium polycrylene. Furthermore, the drug loading of the mirabeeron-sodium polystyrene sulfonate complex is only 86.7%, and a certain amount of free mirabeeron is present in the microparticles. During accelerated processing, the amide bonds in the mirabeeron molecule (the breakage sites for impurity B) are easily hydrolyzed in the presence of water. The introduction of sodium polystyrene sulfonate into the formulation increases the local free water in the system, directly providing a reaction medium for the hydrolysis reaction, thereby accelerating the formation of impurity B.

[0067] Under accelerated conditions, sodium polystyrene sulfonate in Comparative Examples 3 and 5 absorbed some moisture, causing the complex powder to absorb water, become extremely viscous, and form clumps. This "clumping" phenomenon forms a barrier on the surface of the drug particles, severely hindering moisture from penetrating the interior and directly leading to a decrease in the dissolution rate. At 6 months, the dissolution rate exceeded the limit, and the sample quality was unqualified. In Comparative Examples 4 and 6, due to burst release, the dissolution rate of the samples at day 0 already exceeded the limit.

[0068] Compared with Comparative Examples 3-6, Examples 4-15 showed less content decrease during the stability test from day 0 to 3 months of accelerated testing and from 3 months of accelerated testing to 6 months of accelerated testing. The samples were more stable and the content uniformity was better than that of the comparative examples.

[0069] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A mirabezon sustained-release orally disintegrating microtablet, characterized in that, The mirabezone sustained-release orally disintegrating microtablets comprise a mirabezone-ion exchange resin complex and pharmaceutically acceptable excipients; The ion exchange resin is sodium polystyrene sulfonate and potassium polycrylene, and the ratio of sodium polystyrene sulfonate to potassium polycrylene is 1:1 to 5:

1.

2. The Mirabelon sustained-release orally disintegrating microtablets according to claim 1, characterized in that, The content of mirabezine in the mirabezine sustained-release orally disintegrating microtablets is 2wt% to 10wt%, preferably 7.15wt%.

3. The Mirabelon sustained-release orally disintegrating microtablets according to claim 1, characterized in that, The total content of the ion exchange resin is 100wt% to 300wt% of the Miraberon content, preferably 200wt%.

4. The Mirabelon sustained-release orally disintegrating microtablets according to claim 1, characterized in that, The Miraberon-ion exchange resin complex also includes a pH adjuster; The pH adjuster is present in an amount of 0.5 wt% to 3.3 wt% of the mirabezon content. The pH adjuster is one or more of hydrochloric acid, citric acid, and phosphoric acid.

5. The Mirabelon sustained-release orally disintegrating microtablets according to claim 1, characterized in that, Pharmaceutically acceptable excipients include fillers, disintegrants, glidants, and lubricants.

6. The Mirabelon sustained-release orally disintegrating microtablets according to claim 4, characterized in that, The filler is one or more of mannitol, microcrystalline cellulose, sorbitol, and isomalt, preferably mannitol and microcrystalline cellulose.

7. The Mirabelon sustained-release orally disintegrating microtablets according to claim 4, characterized in that, The disintegrant is one or more of crospovidone, crospovidone sodium carboxymethyl cellulose, and sodium carboxymethyl starch.

8. The Mirabelon sustained-release orally disintegrating microtablets according to claim 4, characterized in that, The flow aid is one or more of silica, colloidal silica, and talc. The lubricant is one or more of sodium stearate fumarate, stearic acid, magnesium stearate, and glyceryl behenate.

9. The Mirabelon sustained-release orally disintegrating microtablets according to claim 4, characterized in that, Pharmaceutically acceptable excipients also include compound excipients; The composite excipient is selected from one or more of the following: mannitol-microcrystalline cellulose-crosslinked povidone-colloidal silica composite and mannitol-crosslinked povidone-polyvinyl acetate-povidone composite.

10. A method for preparing mirabezon sustained-release orally disintegrating microtablets according to any one of claims 1-9, characterized in that, Includes the following steps: Miraberon, ion exchange resin, and pH adjuster were placed in a solvent, heated and stirred, and dried to prepare Miraberon-ion exchange resin composite powder. Miraberon-ion exchange resin complex powder was mixed with pharmaceutically acceptable excipients to obtain a mixture, which was then compressed into microplates.